Biomedicine Today reports that Amgen (AMGN) will be shipping the first batch of Temodar in India to treat people with multiple sclerosis (MS). Meanwhile, MS is actually the largest source of cancer treatment in India, accounting for two-thirds of all cancer treatments. MS is the second largest source. The MS drug is shipped through Amgen’s Indian partner, Novartis, who handles other biopharma shipments to India from their Indian partner, Cipla. The collaboration between the two multinational drug companies was signed in 2014.